AI Article Synopsis
- Moderate to severe tricuspid regurgitation (TR) in acute heart failure (AHF) patients leads to worse clinical outcomes, prompting the development of the TRI-SCORE to predict outcomes after tricuspid surgery.
- A study involving 233 hospitalized AHF patients demonstrated that those with higher TRI-SCORE values were associated with increased all-cause mortality during an 8-month follow-up.
- The TRI-SCORE serves as an effective tool for risk stratification, showing significant predictive value for mortality in AHF patients with moderate to severe TR.
Article Abstract
Introduction: Moderate to severe tricuspid regurgitation (TR) in the setting of acute heart failure (AHF) has been found to be associated with worse clinical outcomes. Recently, the TRI-SCORE was developed to predict clinical outcomes after isolated tricuspid surgery.
Objectives: To determine whether this score could aid in risk stratification of AHF patients with moderate-severe TR.
Patients And Methods: A total of 233 hospitalized patients with AHF and moderate-severe TR were included. We calculated the TRI-SCORE for each patient: age ≥70 years, New York Heart Association class ≥III, right-sided heart failure signs, daily furosemide dose ≥125mg, glomerular filtration rate <30 mL/min, elevated total bilirubin concentrations, left ventricular ejection fraction <60%, and moderate/severe right ventricular dysfunction. The primary endpoint was all-cause mortality during follow-up.
Results: The median age was 74 (65; 84) years, 129 (55.4%) were female. During a follow-up of 8 (2; 21) months, 135 (57.9%) patients reached the primary endpoint. Patients with the primary endpoint had a higher TRI-SCORE than those without (8 (6; 9) vs. 6 (4; 7); P <0.001). Multivariable Cox regression analysis showed that a one-point increase in the TRI-SCORE was a significant indicator of all-cause mortality (HR: 1.25; %95 CI:1.14-1.38), P <0.001). Kaplan-Meier analysis showed early divergence of low (0-3), intermediate (4-5) and high (³6) TRI-SCORE curves (log rank P <0.001).
Conclusions: AHF patients with moderate to severe TR have a poor prognosis during follow-up. TRI-SCORE can predict all-cause mortality in these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.20452/pamw.16907 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells.
J Transl Med
January 2025
Department of Hematology Oncology, Affiliated Hospital of Guizhou Medical University, No. 4 Bei Jing Road, Yunyan District, Guiyang, 550004, Guizhou, China.
Background: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy is a common, yet highly efficient, cellular immunotherapy for lymphoma. However, many recent studies have reported on its cardiovascular (CV) toxicity. This study analyzes the cardiotoxicity of CD19 CAR T cell therapy in the treatment of lymphoma for providing a more valuable reference for clinicians.
View Article and Find Full Text PDFJoint analysis of blood pressure changes over time and survival of hypertensive patients under treatment at Sawula hospital in Southern Ethiopia.
BMC Public Health
January 2025
Department of Statistics, Borana University, Borena, Oromia Region, Ethiopia.
Introduction: Hypertension is among the most significant non-communicable public health issues worldwide. High blood pressure, or hypertension, has been associated with severe health consequences, including death, aneurysms, stroke, chronic renal disease, eye damage, heart attack, heart failure, peripheral artery disease, and vascular dementia. Consequently, this study aimed to investigate the predictors linked to survival time and the progression of blood pressure measurements in hypertensive patients.
View Article and Find Full Text PDFTRADD-mediated pyroptosis contributes to diabetic cardiomyopathy.
Acta Pharmacol Sin
January 2025
Department of Pharmacology, School of Pharmacy, Nantong University, Nantong, 226001, China.
Regulated cell death like pyroptosis is one vital cause of diabetic cardiomyopathy (DCM), which eventually leads to heart failure. Tumor necrosis factor (TNF) receptor-associated death domain protein (TRADD) is an adapter protein with multiple functions that participates in the pathophysiological progress of different cardiovascular disorders via regulating regulated cell death. Studies have shown that TRADD combines with receptor-interacting protein kinase 3 (RIPK3) and facilitates its activation, thereby mediating TNF-induced necroptosis.
View Article and Find Full Text PDFSNX3 mediates heart failure by interacting with HMGB1 and subsequently facilitating its nuclear-cytoplasmic translocation.
Acta Pharmacol Sin
January 2025
National and Local United Engineering Lab of Druggability and New Drugs Evaluation, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangdong Province Engineering Laboratory for Druggability and New Drug Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
Sorting nexins (SNXs) as the key regulators of sorting cargo proteins are involved in diverse diseases. SNXs can form the specific reverse vesicle transport complex (SNXs-retromer) with vacuolar protein sortings (VPSs) to sort and modulate recovery and degradation of cargo proteins. Our previous study has shown that SNX3-retromer promotes both STAT3 activation and nuclear translocation in cardiomyocytes, suggesting that SNX3 might be a critical regulator in the heart.
View Article and Find Full Text PDFMaintenance Immunosuppression With Tacrolimus and Everolimus in Heart Transplantation Compared With the Usual Tacrolimus and Micophenolate Protocol: Results From a Retrospective Registry.
Transplant Proc
January 2025
Department of Cardiology, Advanced Heart Failure and Heart Transplant Unit, Hospital Universitario Central de Asturias, Oviedo, Spain; Health Research Institute of Asturias, ISPA, Oviedo, Spain.
Introduction: Real-life data on the long-term use of a maintenance immunosuppressive protocol in heart transplant patients using delayed Everolimus + Tacrolimus are scarce.
Methods: This is a retrospective study that included all heart transplant patients from 2011 to 2021 in two Spanish hospitals. In Hospital A, the preferred immunosuppressive strategy included Everolimus initiation at 2 months post-transplant combined with Tacrolimus and was compared with the results of Hospital B, where a standard Tacrolimus and Mycophenolate mofetil protocol was used.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!